He is a Fellow of the Royal College of Physicians; the American College of Cardiology; the European Society of Cardiology; the International Society for Heart Research and the American Heart Association. He is on the editorial board of a number of major Cardiovascular Journals and has published in excess of 480 peer review papers and edited 23 books. He runs a translational research Institute with his main area of interest including; myocardial protection, the pathophysiology of cardioprotection in the setting of diabetes, ischaemia/reperfusion injury, molecular aspects of adaptation to ischaemic injury and myocardial conditioning in both the basic and clinical arena.
Professor Sir John Cunningham is a clinician-scientist holding positions as Professor of Nephrology at University College London Medical School and The Royal Free Hospital and an Honorary Fellowship at Trinity Hall, University of Cambridge, both in the UK. His early training was in Cambridge (pre-clinical) and Oxford, UK (clinical), with postgraduate training at The University of London and Washington University School of Medicine, St Louis, USA under Drs Louis V Avioli and Eduardo Slatopolsky. He has remained an active frontline clinician in both nephrology and internal medicine. John Cunningham was Physician to HM The Queen and was knighted for services to The Royal Family in June 2014.Academically Professor Cunningham has contributed to the understanding of the effect of acidosis on the bioactivation of vitamin D and described and characterised hysteresis in the parathyroid response to calcium, indicating that parathyroid cells can sense both the direction of change and the absolute concentration of ECF calcium.
He subsequently ran research programmes examining the following: control by structurally modified vitamin D metabolites at PTH synthesis and release; the synthesis and release of bone cytokines by osteoblast like cells and the regulation of these by vitamin D metabolites; the location and relevance of the calcium sensing receptor in bone cells; the influence of simulated uraemia on the release of cytokines by bone cells; the factors mediating bone loss following renal transplantation and preventative strategies; the factors that control parathyroid function in vivo, including new vitamin D metabolites and calcimimetic agents. Professor Cunningham’s group has found that new structurally modified metabolites of vitamin D differ markedly in the way they influence the behaviour of both parathyroid cells and bone cells. His group also devised, conducted and published studies of the first effective prophylaxis against bone loss in the post transplant setting. On these and other subjects, Professor Cunningham frequently lectures nationally and internationally, as well as serving on numerous international expert panels and working groups. He is a founding Co-chairman of the Nephrology At The Limits series held under the auspices of University College London, The University of Cape Town, and The Lancet.
Dr. Peter Libby is a cardiovascular specialist at Brigham and Women’s Hospital in Boston, Massachusetts, and holds the Mallinckrodt Professorship of Medicine at Harvard Medical School. He served as Chief of Cardiovascular Medicine at BWH from 1998 – 2014. His areas of clinical expertise include general and preventive cardiology. His current major research focus is the role of inflammation in vascular diseases such as atherosclerosis. Dr. Libby has a particular devotion to translate laboratory studies to pilot and then large-scale clinical cardiovascular outcome trials.Dr. Libby has received numerous awards and recognitions for his research accomplishments, including most recently the Gold Medal of the European Society of Cardiology (2011), the Basic Research Prize of the American Heart Association (2011), the Anitschkow Prize in Atherosclerosis Research of the European Atherosclerosis Society (2013), and the Special Award of the Heart Failure Association of the European Society of Cardiology (2014). He has received a number of lifetime achievement awards various organizations. Dr. Libby was selected as Consulting Editor of the year by Circulation Research in 2015, and received a 2015 High Citation Award as an editorial board member of Arteriosclerosis Thrombosis, and Vascular Biology. He was awarded the Ernst Jung Gold Medal for Medicine for 2016.
Dr. Libby’s elected professional memberships include the Association of American Physicians, the American Society for Clinical Investigation, and honorary memberships in the British Atherosclerosis Society, the Japan Circulation Society, and the Japanese College of Cardiology. He has served as the President of the Association of University Cardiologists. He also has served in many roles as a volunteer for the American Heart Association, including chairman of several research committees and member of the executive committees of the Councils on Arteriosclerosis, Circulation, and Basic Science. He presided the American College of Cardiology’s Research Allocations Peer Review Committee for two terms. He has frequently consulted for the National Heart, Lung, and Blood Institute, including a 5-year term on the Board of Scientific Councilors. He directed the DW Reynolds Cardiovascular Clinical Research Center and two cycles of Leducq Foundation Awards, and has received continuous funding from the US National Heart Lung and Blood Institute (NHLBI) for several decades.
An author and lecturer on cardiovascular medicine and atherosclerosis, Dr. Libby has published extensively in medical journals including Circulation, Journal of Clinical Investigation, Proceedings of the National Academy of Sciences, New England Journal of Medicine, and Nature. He is an Editor of Braunwald’s Heart Disease, having served as the Editor-in Chief of the 8th Edition. Dr. Libby has also contributed chapters on the pathogenesis, treatment, and prevention of atherosclerosis to many editions of Harrison’s Principles of Internal Medicine. He has held numerous visiting professorships and delivered more than 80 major named or keynote lectures throughout the world.
Dr. Libby earned his medical degree at the University of California, San Diego, and completed his training in internal medicine and cardiology at the Peter Bent Brigham Hospital (now Brigham and Women’s Hospital). He also holds an honorary MA degree from Harvard University, and an honorary doctorate from the University of Lille, France.
Brian Rayner’s active research interests are therapy of hypertension, mutations in the ENaC, genetic determinants of salt sensitivity, HIVAN, vascular calcification and chronic kidney disease, primary aldosteronism, assessing adherence in hypertensive patients, ethics of rationing dialysis therapy, AKI and genetics of severe hypertension in blacks. He has a major interest in hypertension guidelines, and together with Profs Seedat and Veriava wrote the 2014 South African Hypertension Practice Guideline. He has 91 publications in peer reviewed journals, is on the editorial board of the CVS Journal of Africa, and Nephron Clinical Practice, and acts as a reviewer for many peer reviewed international journals, has made over 100 presentations at local and international congresses and has written 6 chapters in books.
Professor Tariq Enver is Director at the University College London Cancer Institute & Professor of Stem Cell Biology. He is also Vice Dean for Research of the UCL Faculty of Medical Sciences, was elected as an EMBO Fellow in 2009 and elected to the 1000 Talents Programme in China.His research career has been principally concerned with understanding the mechanisms by which tissue and developmental stage specific gene expression is achieved and regulated with early work focusing on the regulation of the β-globin gene clusters.
His current work deploys post-genomic technologies and mathematical modelling approaches to gain further insight into how blood stem cells are configured in molecular terms, the nature of the pathways involved in their cell fate decisions, and how these may be used in the pursuit of stem cell therapy and how they are corrupted by chimaeric transcription factors associated with human leukaemia.
Professor Daniel Hochhauser is Co-Director of the Cancer Research UK-UCL Centre, Kathleen Ferrier Professor and consultant medical oncologist at University College London. He has a clinical interest in gastrointestinal oncology. Research areas are in the modulation of DNA interactive agents by novel therapies including inhibition of the epidermal growth factor receptor. Additionally, he has an interest in early phase clinical trials and is currently principal investigator for several novel agents.After qualifying in medicine from Cambridge and the Royal Free Hospital and postgraduate medical training in London and Oxford, he completed research for a DPhil at the Institute of Molecular Medicine in Oxford. Subsequently he worked as a medical oncology fellow at Memorial Sloan Kettering Cancer Center, New York before appointment as consultant in 1996.
Roy S. Herbst, MD, PhD is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Thoracic Oncology Research Program, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.He has led phase I development of several new-generation targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. He was co-leader of BATTLE-1 and co-leads the BATTLE-2 clinical trial program. He served as co-leader of the Developmental Therapeutics Program for the YCC Support Grant. Herbst’s laboratory work focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from preclinical to clinical settings in multiple Phase II and III studies.
Herbst has authored or co-authored more than 300 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.
Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research, where he chairpersons the Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for developmental therapeutics for Southwestern Oncology Group’s (SWOG) Lung Committee, principal investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant.